This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Trygg Pharma, Inc..
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Trygg Pharma, Inc. Identifier:
First received: October 21, 2010
Last updated: November 23, 2011
Last verified: November 2010
The primary objective is to determine the efficacy of AKR963 compared to placebo and active comparator in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 1500 mg/dL.

Condition Intervention Phase
Severe Hypertriglyceridemia Drug: AKR-963 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia

Resource links provided by NLM:

Further study details as provided by Trygg Pharma, Inc.:

Primary Outcome Measures:
  • Difference between AKR963 and Control [placebo or active control] treatment groups in triglyceride lowering effect [ Time Frame: 12 weeks ] [ Time Frame: 12 weeks ]
    The percent change in TG levels from baseline (average of Weeks -2, -1, and 0) to the end of Period A, first 12-week double-blind treatment, (average of Weeks 11 and 12).

Estimated Enrollment: 240
Study Start Date: October 2010
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Active Comparator
Active comparator
Drug: AKR-963
3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
Placebo Comparator: Placebo
Placebo control
Drug: AKR-963
3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
Experimental: AKR-963
Investigational drug
Drug: AKR-963
3600mg/day in capsules of AKR-963, Placebo, or Active Comparator

Detailed Description:
Increases in triglyceride concentrations have been correlated with increased risk for pancreatitis as well as for coronary heart disease (Ginsberg 2001, 2002). The incidence rates for major coronary events in the Munster Heart Study increased from 4.4% among Subjects with baseline TG concentrations under 200 mg/dL to 9.3% among Subjects with TG concentrations in the 200-399 mg/dL range, and up to 13.2% in Subjects with TG levels ranging from 400-799 mg/dL (Assmann 1996).

Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women, ages 18-79
  • Fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL
  • Provide written informed consent and authorization for protected health information disclosure

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant
  • Use of non-statin lipid-altering drugs which cannot be stopped or other supplements with potential lipid-altering effects
  • History of pancreatitis
  • History of bariatric surgery or currently on weight loss drugs or in weight loss programs
  • Treatment with any agent that may affect lipid levels or hepatic function
  • Consumption of more than 3 alcoholic beverages per day
  • History of cancer within last 2 years
  • Participation in another clinical trial involving an investigational agent in the last 30 days
  • Other parameters will be assessed at the study center to ensure eligibility for this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01229566

United States, Illinois
Illinois Recruiting
Chicago, Illinois, United States, 60101
Sponsors and Collaborators
Trygg Pharma, Inc.
Principal Investigator: Kevin C Maki, PhD Addison, Illinois Recruiting
  More Information

Responsible Party: Trygg Pharma, Inc. Identifier: NCT01229566     History of Changes
Other Study ID Numbers: TRGG-963-002
Study First Received: October 21, 2010
Last Updated: November 23, 2011

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on August 18, 2017